Featuring: David Cella, PhD
Study found fewer side effects from new, more effective chemotherapy.
Google “chemotherapy side effects” and the results abound. Nausea, anemia, infection, fertility problems, kidney problems, mouth sores. The list goes on and on.
The seemingly inevitable downside of treating one’s cancer always seems to be a reduction in their quality of life. But a new Northwestern Medicine study published
in Lancet Oncology found that a new combination immune therapy treatment not only extended cancer patients’ lives better than other treatments, it also was less toxic to their overall health than other drugs on the market, providing an added quality-of-life benefit.
“Historically in cancer, most new treatments that extend survival come at a cost,” said lead author David Cella, PhD, chair of Medical Social Sciences. “In this study, we found it’s actually easier on patients, so it has the double benefit.
The quality-of-life study follows an earlier New England Journal of Medicine (NEJM)
study, which found a combination chemotherapy treatment of nivolumab plus cabozantinib doubled the survival rate in patients with previously untreated advanced renal-cell carcinoma when compared to the current standard first-line treatment with sunitinib.
The current Lancet Oncology study examined patient-reported symptoms and side effects from that study. It found those who were given the new treatment, nivolumab plus cabozantinib (experimental), reported their symptoms were stable or had improved while on the treatment, while those taking the existing treatment, sunitinib (control), reported a deterioration in their health status and being bothered by side effects.
“Immune therapy is revolutionizing the treatment of advanced kidney cancer,” Cella said. “For the first time in decades, we are seeing benefits to both survival and quality of life with these new treatments.” People with kidney cancer have more effective treatment options than ever before. Not only are they living longer, they are living better.”
Cella is also associate director for cancer prevention and control research at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.
Funding for the study was provided by Bristol Myers Squibb in collaboration with Ono Pharmaceutical and with Exelixis, Ipsen Pharma and Takeda Pharmaceutical.
This article was originally published in the Robert H. Lurie Comprehensive Cancer Center of Northwestern University News on January 13, 2022.
David Cella, PhD, chair of Medical Social Sciences and lead author of the study.
Northwestern Medicine welcomes the opportunity to partner with you in caring for your patients.